(S)-3-(1'-methylcyclohexanecarbonyl)aminocaprolactam | 876063-98-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-(1'-methylcyclohexanecarbonyl)aminocaprolactam
• 英文别名: (S)-3-(1'-methylcyclohexanecarbonyl)amino-caprolactam；(S)-3-(1-methylcyclohexylcarbonylamino)caprolactam；1-methyl-N-[(3S)-2-oxoazepan-3-yl]cyclohexane-1-carboxamide
• CAS: 876063-98-8
• 化学式: C₁₄H₂₄N₂O₂
• 分子量: 252.357
• InChiKey: DCWQNCVQDSMMDI-NSHDSACASA-N

物化性质

• 熔点：
  168-169 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  507.8±39.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-甲基环己烷羰基氯化物 在 sodium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 12.0h， 以43%的产率得到(S)-3-(1'-methylcyclohexanecarbonyl)aminocaprolactam
  参考文献：
  名称：

  [EN] ANTI-INFLAMMATORY AGENTS
  [FR] AGENTS ANTI-INFLAMMATOIRES

  摘要：

  本发明提供了通式（I）的化合物、组合物及其药学上可接受的盐的用途，其中X为-CO-Y-(R1)n或SO2-Y-(R1)n；Y为0环烷基或多环烷基（例如，金刚烷基，金刚烷甲基，双环辛基，环己基，环丙基）；或为0环烯基或多环烯基。这些化合物是3-氨基己内酯衍生物，用于制备用于治疗炎症性疾病的药物。

  公开号：

  WO2006016152A1

文献信息

• Anti-Inflammatory Agents
  申请人：Grainger David J.

  公开号：US20100016286A1

  公开（公告）日：2010-01-21

  The invention provides compounds, pharmaceutical compositions and uses of compounds and salts thereof of general formula (I), for the preparation of a medicament for treatment of an inflammatory disorder, but excluding (S)-3-(r-methylcyclohexyl-carbonylamino)-caprolactam: wherein z is 1, 2, 3 or 4; A is —CO— or —SO2-; Q is linear or branched alkyl, alkenyl, alkynyl, alkoxy, oxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, haloalkyl, aryl or substituted aryl; T 1 and T 2 together constitute a cycloalkyl, cycloalkenyl or polycycloalkyl radical composed of n additional carbon atoms, where n is between 2 and 7; and each hydrogen atom bonded to the carbon atoms in the ring generated by T 1 and T 2 may be independently be substituted by a group R 1 , where R 1 is independently selected from an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms; or each R 1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical.

  本发明提供了一般式(I)的化合物、药物组合物及其盐的用途，用于制备治疗炎症性疾病的药物，但不包括(S)-3-(r-甲基环己烷甲酰氨基)-己内酯：其中，z为1、2、3或4；A为—CO—或—SO2-；Q为线性或支链烷基、烯基、炔基、烷氧基、氧烷基、氨基烷基、烷基氨基、烷基氨基烷基、卤代烷基、芳基或取代芳基；T1和T2共同构成由n个额外碳原子组成的环状烷基、环状烯基或多环烷基基团，其中n介于2和7之间；并且，T1和T2生成的环上的每个碳原子上的氢原子可以独立地被取代为R1基团，其中R1独立地选自具有1到20个碳原子的烷基、卤代烷基、烷氧基、卤代烷氧基、烯基、炔基或烷基氨基基团；或每个R1独立地选自氟、氯、溴、碘、羟基、氧烷基、氨基、氨基烷基或氨基二烷基基团。
• ANTI-INFLAMMATORY AGENTS
  申请人：Grainger David J.

  公开号：US20110003792A1

  公开（公告）日：2011-01-06

  The invention provides compounds, pharmaceutical compositions and uses of compounds and salts thereof of general formula (I), for the preparation of a medicament for treatment of an inflammatory disorder, but excluding (S)-3-(1′-methylcyclohexylcarbonylamino)-caprolactam: wherein z is 1, 2, 3 or 4; A is —CO— or —SO 2 —; Q is linear or branched alkyl, alkenyl, alkynyl, alkoxy, oxyalkyl, aminoalkyl, alkylamino, alklylaminoalkyl, haloalkyl, aryl or substituted aryl; T 1 and T 2 together constitute a cycloalkyl, cycloalkenyl or polycycloalkyl radical composed of n additional carbon atoms, where n is between 2 and 7; and each hydrogen atom bonded to the carbon atoms in the ring generated by T 1 and T 2 may be independently be substituted by a group R 1 , where R 1 is independently selected from an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms; or each R 1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical.

  本发明提供了通式（I）的化合物、药物组合物及其盐的用途，用于制备治疗炎症性疾病的药物，但不包括（S）-3-（1'-甲基环己基羰基氨基）-己内酯：其中z为1、2、3或4；A为—CO—或—SO2—；Q为线性或支链烷基、烯基、炔基、烷氧基、氧烷基、氨基烷基、烷基氨基、烷基氨基烷基、卤代烷基、芳基或取代芳基；T1和T2共同构成由n个额外碳原子组成的环烷基、环烯基或多环烷基基团，其中n介于2和7之间；而且T1和T2生成的环上每个与碳原子相连的氢原子可以独立地被取代为R1基团，其中R1独立地选自1到20个碳原子的烷基、卤代烷基、烷氧基、卤代烷氧基、烯基、炔基或烷基氨基基团；或每个R1独立地选自氟、氯、溴、碘、羟基、氧烷基、氨基、氨基烷基或氨基二烷基基团。
• Anti-inflammatory Composition
  申请人：Cambridge Enterprise Limited

  公开号：EP2572716A1

  公开（公告）日：2013-03-27

  The invention relates to 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and its use for preparing a medicament intended to prevent or treat inflammatory disorders.

  本发明涉及 3-(2',2'-二甲基丙酰氨基)-四氢吡啶-2-酮及其药物组合物，以及其在制备预防或治疗炎症性疾病的药物中的用途。
• Highly Potent, Orally Available Anti-inflammatory Broad-Spectrum Chemokine Inhibitors
  作者：David J. Fox、Jill Reckless、Hannah Lingard、Stuart Warren、David J. Grainger

  DOI：10.1021/jm900133w

  日期：2009.6.11

  A series of 3-acylaminocaprolactams are inhibitors of chemokine-induced chemotaxis. Branching of the side chain alpha-carbon provides highly potent inhibitors of a range of CC and CXC chemokines. The most potent compound has an ED50 of 40 pM. Selected compounds were tested in an in vivo inflammatory assay, and the best compound reduces TNF-alpha levels with an ED50 of 0.1 mu g/kg when administered by either subcutaneous injection or oral delivery.
• IMPROVED METHODS FOR IDENTIFICATION
  申请人：Cambridge Enterprise Limited

  公开号：EP2401611A1

  公开（公告）日：2012-01-04